Replies to post #31792 on MannKind Corp. (MNKD)

[Profit]

Afrezza has consistent growth be it linear, not exponential growth with ongoing trials for pediatrics. There is nothing stagnant about it. Mannkind is no longer a one trick pony the deal with UTHR has opened up a whole new corridor of growth that pays Mannkind its not hard to understand why Mike kicked the debt down the road. The only thing close to stagnant here is the reason for the current short interest.